Drug intelligence / Profile preview

divalproex sodium + olanzapine

Development stage
Phase 4
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral
01

Overview

Divalproex sodium + olanzapine is a combination of two psychiatric medications: divalproex sodium, a mood stabilizer primarily used as an anticonvulsant and for the treatment of bipolar disorder, and olanzapine, an atypical antipsychotic used for schizophrenia and bipolar disorder. The combination is used, particularly in adults, for the acute treatment of manic or mixed episodes in bipolar I disorder, especially when monotherapy is inadequate. Divalproex sodium increases brain concentrations of gamma-aminobutyric acid (GABA), inhibiting neuronal firing, while olanzapine antagonizes multiple neurotransmitter receptors, most notably dopamine D2 and serotonin 5-HT2A receptors, helping to stabilize mood and reduce psychotic symptoms. The combination aims to provide both mood stabilization and enhanced antipsychotic effects, with studies suggesting earlier and more robust symptom improvement compared to monotherapy, though benefits must be weighed against an increased risk of adverse effects such as weight gain or liver toxicity[1][3][5][9].

Other names
divalproex + olanzapinesodium valproate + olanzapine
02

Targets

ADRA1A (α1A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR3A (5-hydroxytryptamine receptor 3A)HTR6 (5-hydroxytryptamine receptor 6)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on divalproex sodium + olanzapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on divalproex sodium + olanzapine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call